Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)

被引：1

作者：

Panzara, M. ^{[1
]}

Zhang, J. ^{[2
]}

Rinaldi, C. ^{[3
]}

McClorey, G. ^{[3
]}

Bowman, K. ^{[2
]}

Butler, D. ^{[2
]}

Dodart, J. ^{[2
]}

Frank-Kamenetsky, M. ^{[2
]}

Iwamoto, N. ^{[2
]}

Kothari, N. ^{[2
]}

Lu, G. ^{[2
]}

Mathieu, S. ^{[2
]}

M, M. ^{[1
]}

Melkonian, M. ^{[2
]}

Menon, S. ^{[2
]}

Standley, S. ^{[2
]}

Yang, H. ^{[2
]}

Zhong, Z. ^{[2
]}

Wood, M. ^{[3
]}

Vargeese, C. ^{[2
]}

机构：

[1] WAVE Life Sci, Neurol Franchise, Cambridge, MA USA

[2] WAVE Life Sci, Drug Discovery, Cambridge, MA USA

[3] Univ Oxford, Physiol Anat & Genet, Oxford, England

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2017年 / 381卷

关键词：

D O I：

10.1016/j.jns.2017.08.791

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

763

引用

页码：277 / 278

页数：2

共 50 条

[1] WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration
Wood, M.
Zhang, J.
Bowman, K.
Butler, D.
Rinaldi, C.
McClorey, G.
Frank-Kamenetsky, M.
Iwamoto, N.
Kothari, N.
Lu, G.
Mathieu, S.
Meena, M.
Menon, S.
Shimizu, M.
Standley, S.
Yang, H.
Zhong, A.
Francis, C.
Vargeese, C.
NEUROMUSCULAR DISORDERS, 2017, 27 : S217 - S217
[2] Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
Wagner, K.
Phan, H.
Servais, L.
Gidaro, T.
Cripe, L.
Eagle, M.
Muntoni, F.
Straub, V.
Lonkar, P.
Schmitz, S.
Lake, S.
Hu, X.
Panzara, M.
NEUROMUSCULAR DISORDERS, 2019, 29 : S124 - S124
[3] Optimization of preclinical antisense oligonucleotide development for Duchenne muscular dystrophy
Kolfschoten, I. G. M.
Janson, A. A. M.
van den Eijnde, R. E. Y.
Bijl, S.
Zonneveld-Mulder, M. H. C.
de Visser, P. C.
van Deutekom, J. C. T.
NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 803 - 804
[4] Design of a Phase 2/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping
Wagner, K.
Cripe, L.
Eagle, M.
Muntoni, F.
Niks, E.
Phan, H.
Straub, V.
Hu, X.
Antonijevic, I.
Berry, S.
Quintana, M.
Lake, S.
Panzara, M.
NEUROMUSCULAR DISORDERS, 2019, 29 : S176 - S177
[5] WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)
Liu, Yuanjing
Andreucci, Amy
Iwamoto, Naoki
Yin, Yuan
Yang, Hailin
Liu, Fangjun
Patil, Saurabh
Mohapatra, Susovan
Purcell-Estabrook, Erin
Taborn, Kristin
Dale, Elena
Vargeese, Chandra
NEUROLOGY, 2021, 96 (15)
[6] Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
Aoki, Yoshitsugu
Yokota, Toshifumi
Wood, Matthew J. A.
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[7] PGN-EDO51: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD)
Holland, Ashling
Godfrey, Caroline
Lonkar, Pallavi
Svenstrup, Niels
Larkindale, Jane
McArthur, James
Bracegirdle, Sonia
Goyal, Jaya
NEUROLOGY, 2023, 100 (17)
[8] PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy
Hammond, Suzan M.
Wood, Matthew J. A.
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (04) : 478 - 486
[9] A historical perspective on the development of antisense oligonucleotide treatments for Duchenne muscular dystrophy and spinal muscular atrophy
Aartsma-Rus, Annemieke
Takeda, Shin'ichi
JOURNAL OF NEUROMUSCULAR DISEASES, 2025,
[10] Development of gene editing approaches for the treatment of Duchenne muscular dystrophy (DMD)
Moore, M.
Vallese, D.
Kymalainen, H.
Dickson, G.
Popplewell, L.
NEUROMUSCULAR DISORDERS, 2016, 26 : S15 - S15

← 1 2 3 4 5 →